Bristol To Submit Ixabepilone In First Half Of 2007 For Metastatic Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm reports statistically significant Phase III data for ixabepilone/Xeloda combination at American Society of Clinical Oncology meeting in Chicago.